CINECA IRIS Institutional Research Information System

BERTAMINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.069
EU - Europa 1.050
NA - Nord America 730
SA - Sud America 185
AF - Africa 36
OC - Oceania 23
Totale 3.093
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 632
CN - Cina 480
IT - Italia 347
JP - Giappone 150
IN - India 141
GB - Regno Unito 139
ES - Italia 94
FR - Francia 90
BR - Brasile 76
DE - Germania 72
HK - Hong Kong 64
TR - Turchia 55
SG - Singapore 53
IE - Irlanda 49
MX - Messico 45
CO - Colombia 42
CA - Canada 41
NL - Olanda 34
SE - Svezia 31
GR - Grecia 28
VN - Vietnam 26
PT - Portogallo 21
AR - Argentina 20
FI - Finlandia 20
AU - Australia 18
BE - Belgio 18
RU - Federazione Russa 18
TW - Taiwan 18
CH - Svizzera 14
AT - Austria 13
CL - Cile 13
IL - Israele 13
BO - Bolivia 12
TH - Thailandia 12
VE - Venezuela 11
DZ - Algeria 10
EC - Ecuador 10
EG - Egitto 9
CZ - Repubblica Ceca 8
HR - Croazia 8
HU - Ungheria 8
SA - Arabia Saudita 8
PL - Polonia 7
KR - Corea 6
MY - Malesia 6
RS - Serbia 6
UA - Ucraina 6
NZ - Nuova Zelanda 5
TZ - Tanzania 5
AE - Emirati Arabi Uniti 4
IR - Iran 4
MA - Marocco 4
MM - Myanmar 4
NO - Norvegia 4
TN - Tunisia 4
BD - Bangladesh 3
CR - Costa Rica 3
GT - Guatemala 3
ID - Indonesia 3
JO - Giordania 3
PH - Filippine 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
UZ - Uzbekistan 3
AM - Armenia 2
CY - Cipro 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
MQ - Martinica 2
NG - Nigeria 2
NI - Nicaragua 2
PA - Panama 2
RO - Romania 2
SI - Slovenia 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
LT - Lituania 1
MK - Macedonia 1
RE - Reunion 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 3.093
Salva come PNG Salva come JPEG
Città #
Beijing 82
Shanghai 55
Dublin 45
Madrid 40
Turin 40
London 37
Tokyo 34
São Paulo 33
Mumbai 31
Chandler 30
Milan 30
Chicago 28
Florence 28
Bogotá 25
Central 24
Singapore 24
Hangzhou 23
Paris 21
Guangzhou 20
Istanbul 19
Hyderabad 18
New York 18
Manchester 17
Seattle 17
Nyköping 16
Tianjin 16
Chongqing 15
Dallas 15
Los Angeles 14
Ludhiana 14
Athens 13
Delhi 13
Houston 13
Nanjing 13
Pittsburgh 13
Ashburn 12
Bologna 12
Moscow 12
Osaka 12
Rome 12
Atlanta 11
Barcelona 11
Hanoi 11
Helsinki 11
Medford 11
Mexico City 11
Umeda 11
Brussels 10
Chennai 10
Santiago 10
Vienna 10
Ankara 9
Boston 9
Breda 9
Buffalo 9
Curitiba 9
Fairfield 9
Hong Kong 9
San Jose 9
Sydney 9
Wuhan 9
Bangkok 8
Bari 8
Chengdu 8
Cologne 8
Lexington 8
Munich 8
Ann Arbor 7
Cambridge 7
Cuenca 7
Glasgow 7
Gurugram 7
Lille 7
Monterrey 7
Montreal 7
Pisa 7
Princeton 7
Pune 7
Reston 7
Shaoxing 7
Aachen 6
Biskra 6
Buenos Aires 6
Frankfurt am Main 6
Hamburg 6
Indianapolis 6
Kolkata 6
La Paz 6
Memphis 6
Nanning 6
Parma 6
Potenza 6
San Francisco 6
Santa Cruz 6
Shenzhen 6
Torino 6
Toronto 6
Valencia 6
Washington 6
Xi'an 6
Totale 1.420
Salva come PNG Salva come JPEG
Nome #
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial 1.588
MRD Assessment in Multiple Myeloma: Progress and Challenges 1.132
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients 126
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies 81
Moving Toward Continuous Therapy in Multiple Myeloma 58
Checkpoint inhibitors and myeloma: promises, deadlocks and new directions 43
When and How to Treat Relapsed Multiple Myeloma 33
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial 26
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 24
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 10
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells 8
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 4
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 2
Totale 3.135
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.141
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.141
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202015 0 0 0 0 0 0 0 0 9 3 3 0
2020/202144 3 1 1 2 1 0 1 6 3 4 3 19
2021/2022139 7 3 3 4 12 3 7 5 10 15 15 55
2022/20231.174 12 12 31 104 113 107 144 108 119 134 144 146
2023/20241.676 116 151 141 179 179 127 141 143 55 128 157 159
2024/202587 87 0 0 0 0 0 0 0 0 0 0 0
Totale 3.135